For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Abraxane Supply Secured until around July: Taiho
January 26, 2022
- Astellas Aims to Propel Digital Transformation to Become Value-Driven Innovator
January 25, 2022
- Aculys Pharma Gets APAC Rights to Neurelis’ Epilepsy Nasal Spray
January 25, 2022
- Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
- Daiichi Sankyo to End Vaccine Collaboration with Kitasato Pharma
January 24, 2022
- JCR’s MPS IIIA Drug Gets Orphan Tag in Europe
January 24, 2022
- Shipment Control Lifted for Pfizer's Methotrexate Injection After One Year
January 21, 2022
- Shionogi Submits PI Data for Oral COVID-19 Drug in Japan
January 21, 2022
- Fractale Grabs Japan Commercial Rights to SaNOtize’s Anti-COVID Nasal Spray
January 21, 2022
- FunPep, EPS Group in Talks to Codevelop Peptide Drugs in China
January 21, 2022
- BMS’ Second CAR-T Therapy Abecma Approved in Japan
January 21, 2022
- Fuji Pharma Slapped with Biz Improvement Order over GMP Violations
January 20, 2022
- Daiichi Sankyo to Offload 8 US Assets to Cosette
January 20, 2022
- Katarzyna Maria Witkos Takes Helm at Alnylam Japan
January 20, 2022
- First Subject Enrolled in US PII/III of Anti-MTBR Tau Antibody for Alzheimer’s: Eisai
January 20, 2022
- AnGes/Vasomune's COVID-19 Med Enters PIIa for Severe Hospitalized Patients in US
January 20, 2022
- SymBio Seeks to Start PII Trial for Pediatric Adenovirus Infections in UK
January 19, 2022
- Mitsubishi Tanabe Earns Japan Rights for ADC Zynlonta
January 19, 2022
- Ono, Neurimmune Extend Drug Discovery Pact for Neurodegenerative Diseases
January 18, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…